[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin,2015,65: 5-29.
[2] 中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)摘要. 中华肝脏病杂志,2012,20: 419-426.
[3] Trinchet JC, Alperovitch A, Bedossa P, et al. Epidemiology, prevention, screening and diagnosis of hepatocellular carcinoma. Bull Cancer,2009,96: 35-43.
[4] Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut,2014,63: 844-855.
[5] Anborgh PH, Mutrie JC, Tuck AB, et al. Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal,2011,5: 111-122.
[6] Muramatsu T. Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem,2002,132: 359-371.
[7] Sherman M. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol,2014,28: 783-793.
[8] El-Tanani MK. Role of osteopontin in cellular signaling and metastatic phenotype. Front Biosci,2008,13:4276-4284.
[9] Abu EI Makarem MA, Abdel-Aleem A, Ali A, et al. Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Ann Hepatol,2011,10: 296-305.
[10] Shang S, Plymoth A, Ge S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology,2012,55: 483-490.
[11] Jia HL, Ye QH, Qin LX, et al. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res,2007,13: 1133-1139.
[12] Zhu WW, Guo JJ, Guo L, et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res,2013,19: 3944-3954. |
